PMID- 33159281
OWN - NLM
STAT- MEDLINE
DCOM- 20210518
LR  - 20210518
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 40
IP  - 6
DP  - 2021 Jun
TI  - Efficacy and safety of tanezumab administered as a fixed dosing regimen in 
      patients with knee or hip osteoarthritis: a meta-analysis of randomized 
      controlled phase III trials.
PG  - 2155-2165
LID - 10.1007/s10067-020-05488-4 [doi]
AB  - This study aims to evaluate the efficacy and safety of tanezumab administered as 
      a fixed dosing regimen in patients with knee or hip osteoarthritis. Randomized 
      controlled phase III trials (RCTs) that evaluated the efficacy and safety 
      associated with tanezumab for knee or hip OA were systematically identified by 
      searching electronic databases, including Cochrane Library, PubMed, and Embase, 
      for 30 years from December 1990 up to July 2020. Ten relevant studies were 
      included in our meta-analysis. The research was reported based on the preferred 
      Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to 
      ensure the reliability and verity of results. Our study showed that the tanezumab 
      groups were more effective than the placebo groups in terms of mean change from 
      the baseline in Western Ontario and McMaster Universities Osteoarthritis Index 
      (WOMAC) pain (P < .00001), WOMAC physical functional (P < .00001), and patient's 
      global assessment (PGA) (P < .00001). Discontinued due to adverse events (AEs) (P 
      < .00001), serious AEs (P = .02), abnormal peripheral sensations (both P < 
      .00001), and peripheral neuropathy (P < .002) in tanezumab groups were 
      significantly higher than that in control groups. Compared with placebo, 
      tanezumab can effectively relieve pain and improve WOMAC physical function and 
      patient's global assessment (PGA) in knee and hip osteoarthritis. Meanwhile, 
      adverse events are transient in nature and generally well-tolerated. However, we 
      still need large-sample, high-quality studies to investigate the long-term safety 
      of tanezumab to give the conclusion.
FAU - Fan, Zheng-Rui
AU  - Fan ZR
AD  - Biomechanics Labs of Orthopaedics Institute, Tianjin Hospital, Tianjin, 300050, 
      People's Republic of China.
AD  - Tianjin Hospital, Tianjin University, Tianjin, 300211, People's Republic of 
      China.
AD  - Tianjin Medical University, Tianjin, 300211, People's Republic of China.
FAU - Ma, Jian-Xiong
AU  - Ma JX
AD  - Biomechanics Labs of Orthopaedics Institute, Tianjin Hospital, Tianjin, 300050, 
      People's Republic of China.
AD  - Tianjin Hospital, Tianjin University, Tianjin, 300211, People's Republic of 
      China.
FAU - Wang, Ying
AU  - Wang Y
AD  - Biomechanics Labs of Orthopaedics Institute, Tianjin Hospital, Tianjin, 300050, 
      People's Republic of China.
AD  - Tianjin Hospital, Tianjin University, Tianjin, 300211, People's Republic of 
      China.
FAU - Chen, Heng-Ting
AU  - Chen HT
AD  - Biomechanics Labs of Orthopaedics Institute, Tianjin Hospital, Tianjin, 300050, 
      People's Republic of China.
AD  - Tianjin Hospital, Tianjin University, Tianjin, 300211, People's Republic of 
      China.
AD  - Tianjin Medical University, Tianjin, 300211, People's Republic of China.
FAU - Lang, Shuang
AU  - Lang S
AD  - Biomechanics Labs of Orthopaedics Institute, Tianjin Hospital, Tianjin, 300050, 
      People's Republic of China.
AD  - Tianjin Hospital, Tianjin University, Tianjin, 300211, People's Republic of 
      China.
FAU - Ma, Xin-Long
AU  - Ma XL
AD  - Biomechanics Labs of Orthopaedics Institute, Tianjin Hospital, Tianjin, 300050, 
      People's Republic of China. 517494450@qq.com.
AD  - Tianjin Hospital, Tianjin University, Tianjin, 300211, People's Republic of 
      China. 517494450@qq.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20201106
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - EQL0E9GCX1 (tanezumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - Clinical Trials, Phase III as Topic
MH  - Double-Blind Method
MH  - Humans
MH  - *Osteoarthritis, Hip/drug therapy
MH  - *Osteoarthritis, Knee/drug therapy
MH  - Pain Measurement
MH  - Randomized Controlled Trials as Topic
MH  - Reproducibility of Results
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Hip
OT  - Knee
OT  - Nerve growth factor
OT  - Osteoarthritis
OT  - Randomized controlled trials
OT  - Tanezumab
EDAT- 2020/11/08 06:00
MHDA- 2021/05/19 06:00
CRDT- 2020/11/07 05:34
PHST- 2020/08/05 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/10/22 00:00 [revised]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2021/05/19 06:00 [medline]
PHST- 2020/11/07 05:34 [entrez]
AID - 10.1007/s10067-020-05488-4 [pii]
AID - 10.1007/s10067-020-05488-4 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2021 Jun;40(6):2155-2165. doi: 10.1007/s10067-020-05488-4. Epub 
      2020 Nov 6.